Doctor Addresses Controversy Around MOTS-c Dosing (WATCH BEFORE TAKING)

Key wellness strategies & guidance from the subtitles

1) Don’t assume “more frequent is better” for MOTS-c / Matzi dosing

The speaker argues that steadier, more frequent injections (e.g., daily or 3x/week) can reduce effectiveness.

• They claim that the injection gap is part of the protocol, not “downtime.”
• Relying on internet dosing schedules may lead to using a frequency without understanding the rationale, which can cause results to stall.

2) Use dosing frequency as a “signal,” not as a constant drug level

MOTS-c is described as a cellular energy “low fuel” signal, acting through AMPK/energy-scarcity pathways.

• A signal works best when it isn’t always on.
• Too-frequent dosing may cause cells to stop treating it as meaningful information.

3) Watch for two different failure patterns (and troubleshoot differently)

The speaker suggests separating outcomes into two main patterns:

1. Worked for ~2 weeks, then stopped (“flat”)

   • Likely blamed on injecting too often (a frequency issue).

2. Didn’t help from the start or made you feel worse

   • Likely blamed on a weak “foundation,” such as impaired mitochondria/energy system function from factors like:
     • Long-term stress
     • Undereating

“Foundation first” concept:

Peptides are positioned as amplifiers—if the underlying system is damaged, peptides may underperform or worsen symptoms.

4) Clinic approach: limit to 1–2 injections per week (with specific options)

Default recommendation:

• 1–2 injections per week, maximum
• The speaker states this outperforms what they see others doing.

Two main dosing formats (same weekly total, different spacing):

• Option 1: 10 mg once weekly
• Option 2: 5 mg twice weekly

Rule for choosing:

• Select the schedule you can follow consistently.

Front-loading / priming (temporary start-up adjustment):

• Only at the very beginning, a temporary “priming phase” is mentioned:
  • Up to 10 mg three times/week initially
  • Then drop back to 10 mg/week
• Important distinction:
  • If you’re still doing 3x/week after starting, that is no longer front-loading.

5) Storage & vial-handling: focus on heat/light/handling, not “days in the fridge” myths

The speaker disputes the idea that MOTS-c is quickly “lost” in the refrigerator.

Key points for vial handling:

• Keep the vial cold (avoid heat exposure like hot cars)
• Keep it dark
• Avoid shaking
• Inspect before each draw:
  • The vial should be clear
  • If cloudy, has floating particles, or shows color changes, the vial is done

Why blood/plasma claims don’t always transfer:

Stability findings from blood/plasma testing don’t necessarily reflect how vials behave in a fridge—blood contains enzymes that can break peptides down.

6) Practical self-care/productivity behavior: consistency + real-time support

The speaker emphasizes:

• Don’t just copy a schedule—understand the “why.”
• If unsure, get support rather than guessing or troubleshooting blindly.

7) Help-seeking workflow (clinic/medical team process)

How to get answers:

• Use their 503A pharmacy and medical team support when questions come up.

Workflow described:

1. Free discovery call with patient educators (fit/read on goals)
2. If it’s a fit: an intake call where the medical team designs the protocol
3. Coaching is available for deeper weight/maintenance-focused goals

They also note that sequencing other mitochondrial peptides matters—examples include:

• SS31
• MC (“M C”)
• NAD

A common reason things “fall flat,” per the speaker, is incorrect peptide sequencing.

---

Presenters / sources

• Dr. Jones DC (speaker; runs clinic protocols and coaching)
• 503A partner pharmacy (medical prescription/distribution source mentioned)
• Laboratories / drug-testing and blood-plasma studies (referenced generally to explain where “storage instability” claims originated; no specific lab named)